Abstract:The molecular and cellular pathways that support the maintenance and stability of tumor neovessels are not well defined. The efficacy of microtubule-disrupting agents, such as combretastatin A4 phosphate (CA4P), in inducing rapid regression of specific subsets of tumor neovessels has opened up new avenues of research to identify factors that support tumor neoangiogenesis. Herein, we show that CA4P selectively targeted endothelial cells, but not smooth muscle cells, and induced regression of unstable nascent tumor neovessels by rapidly disrupting the molecular engagement of the endothelial cell-specific junctional molecule vascular endothelial-cadherin (VE-cadherin) in vitro and in vivo in mice. CA4P increases endothelial cell permeability, while inhibiting endothelial cell migration and capillary tube formation predominantly through disruption of VE-cadherin/beta-catenin/Akt signaling pathway, thereby leading to rapid vascular collapse and tumor necrosis. Remarkably, stabilization of VE-cadherin signaling in endothelial cells with adenovirus E4 gene or ensheathment with smooth muscle cells confers resistance to CA4P. CA4P synergizes with low and nontoxic doses of neutralizing mAbs to VE-cadherin by blocking assembly of neovessels, thereby inhibiting tumor growth. These data suggest that the microtubule-targeting agent CA4P selectively induces regression of unstable tumor neovessels, in part through disruption of VE-cadherin signaling. Combined treatment with anti-VE-cadherin agents in conjunction with microtubule-disrupting agents provides a novel synergistic strategy to selectively disrupt assembly and induce regression of nascent tumor neovessels, with minimal toxicity and without affecting normal stabilized vasculature.

Recent advances of combretastatin A4-type vascular disrupting agents

AVE8062: a new combretastatin derivative vascular disrupting agent

Synthesis and mechanistic studies of novel spin-labeled combretastatin derivatives as potential antineoplastic agents.

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.

Design, Synthesis, And Biological Evaluation Of Hydantoin Bridged Analogues Of Combretastatin A-4 As Potential Anticancer Agents

Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules

Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect

Tumor Resistance to Vascular Disrupting Agents: Mechanisms, Imaging, and Solutions.

Advances In Combination Of Antiangiogenic Agents Targeting Vegf-Binding And Conventional Chemotherapy And Radiation For Cancer Treatment

CA-1H, a Novel Oxazole Bearing Analogue of Combretastatin A-4, Disrupts the Tumor Vasculatures and Inhibits the Tumor Growth Via Inhibiting Tubulin Polymerization.

Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents

The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors.

Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo

Endostar Enhances the Antineoplastic Effects of Combretastatin A4 Phosphate in an Osteosarcoma Xenograft.

Combretastatin A4-combined photodynamic therapy for enhanced tumor therapeutic efficacy

Novel Combretastatin A-4 Analogs—Design, Synthesis, and Antiproliferative and Anti-Tubulin Activity

Design, synthesis, and anti-breast tumor activity of novel combretastatin A-4 analogues

Novel Combretastatin A-4 Derivative XN0502 Induces Cell Cycle Arrest and Apoptosis in A549 Cells.

Design, Synthesis, Biological Evaluation and Cocrystal Structures with Tubulin of Chiral Β-Lactam Bridged Combretastatin A-4 Analogues As Potent Antitumor Agents.

Design, synthesis of combretastatin A-4 piperazine derivatives as potential antitumor agents by inhibiting tubulin polymerization and inducing autophagy in HCT116 cells

In Vitro Anticancer Effect of Combretastatin A4 Liposomes in Destruction of Vascular Mimicry in Triple-Negative Breast Cancer Cells